Anaconda Pharma

Anaconda Pharma has moved to new facilities in the BioPark (Paris) - April 28^th, 2008 -

The new address of Anaconda Pharma is:

Anaconda Pharma

11, rue Watt

75013 PARIS  -  France

Tel : +33 (0)1 75 57 86 54

Fax: +33 (0)1 75 57 86 55

‘Pôle de Compétitivité’ Medicen Paris Region Award  – May 4^th,  2007 –

Anaconda Pharma (the “Company”) is pleased to announce that the CondyClin Project has received formal recognition from the ‘Pôle de Compétitivité’ Medicen Paris Region. The CondyClin project is focused on the clinical development of AP611, Anaconda’s small molecule drug candidate to treat subjects with condyloma. The Dermatology and Allergology Department of the Tenon Hospital (Paris) will collaborate with Anaconda Pharma on this project. Dr. Marta Blumenfeld, CEO of Anaconda Pharma comments; “This is substantial recognition of the progress and the importance of the efforts being made by Anaconda Pharma to develop a specific anti-condyloma drug. We expect this award will help us to obtain public funding to finance in-part the upcoming clinical trial program of AP611”.

Anaconda Pharma (www.anacondapharma.com) is a privately held biopharmaceutical company incorporated in November 2003 and operating from lab space within the BioTop incubator at the Pasteur Institute campus in Paris, France. Anaconda Pharma has developed a unique and proprietary platform for the discovery of small molecules that disrupt protein:protein interactions. These represent a major new class of pharmaceutical targets which have been unexploited due to the difficulty of recognizing drug'able hot-spots on the surface of interacting proteins.

Anaconda Pharma is initially targeting condyloma, an HPV related-indication which represents the major HPV economic opportunity in industrialized countries.

Financing – October 1^st, 2006 –
Anaconda Pharma (the “Company”) is pleased to announce that it successfully secured its position as Leader of the CristaLead Program, a project recognized by a label from the ‘Pôle de Compétitivité’ Medicen Paris Region early in 2006 and now financed by the French Ministry of Industry.  In addition to Anaconda Pharma, the CristaLead Program gathers the knowledge and skills in chemo-informatics, chemistry and biology of private companies Ariana Pharma and Medit, and public laboratories Institut Pasteur and ICSN (CNRS). The goal of CristaLead is to develop novel antiviral compounds and screening and chemo-informatics tools based on an innovative mechanism of action for drug discovery : protein-protein interactions. This program will yield to Anaconda Phama a minimum of €960,000 in non-repayable, non-dilutive grant financing over the coming 3 years. Dr. Marta Blumenfeld, CEO comments; “This is great news for Anaconda Pharma and recognition of the first class, leading edge science being done at the company in the emerging field of protein-protein interactions.  We look forward to working with our partners in this program to develop some truly innovative science over the coming 3 years”.

Anaconda Pharma (www.anacondapharma.com) is a privately held biopharmaceutical company incorporated in November 2003 and operating from lab space within the BioTop incubator at the Pasteur Institute campus in Paris, France.                 
Anaconda Pharma has developed a unique and proprietary platform for the discovery of small molecules that disrupt protein:protein interactions. These represent a major new class of pharmaceutical targets which have been unexploited due to the difficulty of recognizing drug'able hot-spots on the surface of interacting proteins.

Anaconda Pharma’s unique technology platform includes:
    - proprietary high definition crystallographic 3-D information on targets,
    - proprietary cellular and in vitro screening assays, and
    - patented lead molecules & series amenable to optimisation.